Drug Trial Radar · NCT06215586
Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
303
Actual
Start
Feb 13, 2024
Primary completion
Sep 2, 2025
Study completion Sep 2, 2025
Sponsor
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with preserved ejection fraction
Conditions
- Heart Failure
- Heart Failure Preserved Ejection Fraction
- Cardiovascular Diseases
- Heart Diseases
Interventions
Tovinontrine (CRD-750)Drug
Tablet administered orally
PlaceboDrug
Tablet administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in biomarkers from Baseline to Week 12 - NT-proBNPTime frame: Baseline to Week 12
Locations
84 sites in 15 countries. Site status is shown where the registry gives one.
Cardurion Investigative Site
Birmingham, Alabama
Cardurion Investigative Site
Little Rock, Arkansas
Cardurion Investigative Site
Orange, California
Cardurion Investigative Site
Torrance, California
Cardurion Investigative Site
Van Nuys, California
Cardurion Investigative Site
Jacksonville, Florida
Cardurion Investigative Site
Miami, Florida
Cardurion Investigative Site
Hazel Crest, Illinois
Cardurion Investigative Site
Peoria, Illinois
Cardurion Investigative Site
Alexandria, Louisiana
Cardurion Investigative Site
Covington, Louisiana
Cardurion Investigative Site
St Louis, Missouri
Cardurion Investigative Site
Buffalo, New York
Cardurion Investigative Site
New York, New York
Cardurion Investigative Site
Cleveland, Ohio
Cardurion Investigative Site
Oklahoma City, Oklahoma
Cardurion Investigative Site
Portland, Oregon
Cardurion Investigative Site
Rapid City, South Dakota
Cardurion Investigative Site
Nashville, Tennessee
Cardurion Investigative Site
Dallas, Texas
Cardurion Investigative Site
McKinney, Texas
Cardurion Investigative Site
Burlington, Vermont
Cardurion Investigative Site
Chermside, Australia
Cardurion Investigative Site
Bruges, Belgium
Cardurion Investigative Site
Sint-Niklaas, Belgium
Cardurion Investigative Site
Burgas, Bulgaria
Cardurion Investigative Site
Gabrovo, Bulgaria
Cardurion Investigative Site
Plovdiv, Bulgaria
Cardurion Investigative Site
Plovdiv, Bulgaria
Cardurion Investigative Site
Rousse, Bulgaria
Cardurion Investigative Site
Sofia, Bulgaria
Cardurion Investigative Site
Stara Zagora, Bulgaria
Cardurion Investigative Site
Cambridge, Ontario, Canada
Cardurion Investigative Site
Hamilton, Ontario, Canada
Cardurion Investigative Site
Chicoutimi, Quebec, Canada
Cardurion Investigative Site
Montreal, Quebec, Canada
Cardurion Investigative Site
Sherbrooke, Quebec, Canada
Cardurion Investigative Site
Trois-Rivières, Quebec, Canada
Cardurion Investigative Site
Hradec Králové, Czechia
Cardurion Investigative Site
Hradec Králové, Czechia
Showing 40 of 84 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.